Table 1. Demographic and clinical characteristics of all subjects.
| Groups | PD-A(n=18) | PD-NA(n=45) | HC(n=24) | P value |
|---|---|---|---|---|
| Gender (M/F) | 12, 6 | 34, 11 | 10,14 | 0.02a |
| Age (y) | 71.74±5.16 | 66.17±8.11 | 65.33±4.65 | 0.01b |
| Education (y) | 12.84±2.95 | 11.52±3.56 | 10.79±2.92 | 0.13b |
| Disease duration (y) | 3.76±3.23 | 3.94±2.87 | NA | 0.83c |
| H&Y staging | 2.45±0.60 | 2.11±0.71 | NA | 0.14c |
| UPDRS-III | 24.05±8.92 | 21.52±10.59 | NA | 0.36c |
| Total LEDD (mg/d) | 450.17±252.08 | 373.95±306.93 | NA | 0.34c |
| LEDD of DA (mg/d) | 33.55±43.91 | 40.90±40.95 | NA | 0.52c |
| LEDD of LP (mg/d) | 346.05±156.85 | 257.32±223.62 | NA | 0.13c |
| MMSE | 27.79±1.87 | 28.24±1.57 | NA | 0.32c |
| FAB | 27.79±1.87 | 28.24±1.57 | NA | 0.32c |
| HAMD | 9.26±2.64 | 3.83±3.19 | 1.54±2.06 | <0.001b |
| HAMA | 15.47±3.01 | 5.93±3.42 | 2.33±2.04 | <0.001b |
Data are presented as mean ± s.d..
Abbreviations: PD-A, Parkinson's disease with anxiety; PD-NA, Parkinson's disease without anxiety; HC, Healthy controls; NA, Not applicable; M, Male; F, Female; y, year; H&Y, Hoehn and Yahr; LEDD, Levodopa equivalent daily dose; DA, Dopamine receptor agonists; LP, Levodopa preparations; UPDRS, Unified Parkinson's Disease Rating Scale; MMSE, Mini Mental State Examination; FAB, Frontal Assessment Battery; HAMD, 17-item Hamilton Depression Rating Scale; HAMA, Hamilton Anxiety Rating Scale.
P < 0.05 was considered significant. achi-square test; bone-way analysis of variance test (ANOVA); ctwo-sample t-test.